
Tourette Syndrome - Pipeline Insight, 2025
Description
DelveInsight’s, “Tourette syndrome - Pipeline Insight, 2025,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Tourette syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Tourette syndrome: Overview
Tourette syndrome (TS) is a hereditary neurologic movement disorder characterized by repetitive motor and vocal tics. Symptoms may include involuntary movement of the extremities, shoulders, and face accompanied by uncontrollable sounds and/or inappropriate words. Symptoms tend to be variable and follow a chronic waxing and waning course. The exact cause of Tourette syndrome isn't known, but some research suggests that it happens when there's a problem with how nerves communicate in certain areas of the brain. An upset in the balance of neurotransmitters (chemicals in the brain that carry nerve signals from cell to cell) might play a role. To be diagnosed with Tourette syndrome, a person must have several different types of tics — specifically, multiple motor tics and at least one vocal tic for at least a year. They may happen every day or from time to time throughout the year. There isn't a specific test for Tourette syndrome. Instead, the doctor looks at the family history, the medical history, and the person's symptoms to make a diagnosis. Sometimes, imaging tests like magnetic resonance imaging tests (MRIs), computerized tomography (CT) scans, electroencephalograms (EEGs), or blood tests can rule out other conditions that might cause symptoms similar to TS. The only FDA-approved medications for TS are the classical neuroleptic antipsychotic drugs, haloperidol and pimozide, which block D2 dopamine receptors.
""Tourette syndrome - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tourette syndrome pipeline landscape is provided which includes the disease overview and Tourette syndrome treatment guidelines. The assessment part of the report embraces, in depth Tourette syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tourette syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Tourette syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tourette syndrome Emerging Drugs
Further product details are provided in the report……..
Tourette syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Tourette syndrome drugs segregated based on following parameters that define the scope of the report, such as:
Tourette syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tourette syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tourette syndrome drugs.
Tourette syndrome Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Tourette syndrome: Overview
Tourette syndrome (TS) is a hereditary neurologic movement disorder characterized by repetitive motor and vocal tics. Symptoms may include involuntary movement of the extremities, shoulders, and face accompanied by uncontrollable sounds and/or inappropriate words. Symptoms tend to be variable and follow a chronic waxing and waning course. The exact cause of Tourette syndrome isn't known, but some research suggests that it happens when there's a problem with how nerves communicate in certain areas of the brain. An upset in the balance of neurotransmitters (chemicals in the brain that carry nerve signals from cell to cell) might play a role. To be diagnosed with Tourette syndrome, a person must have several different types of tics — specifically, multiple motor tics and at least one vocal tic for at least a year. They may happen every day or from time to time throughout the year. There isn't a specific test for Tourette syndrome. Instead, the doctor looks at the family history, the medical history, and the person's symptoms to make a diagnosis. Sometimes, imaging tests like magnetic resonance imaging tests (MRIs), computerized tomography (CT) scans, electroencephalograms (EEGs), or blood tests can rule out other conditions that might cause symptoms similar to TS. The only FDA-approved medications for TS are the classical neuroleptic antipsychotic drugs, haloperidol and pimozide, which block D2 dopamine receptors.
""Tourette syndrome - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tourette syndrome pipeline landscape is provided which includes the disease overview and Tourette syndrome treatment guidelines. The assessment part of the report embraces, in depth Tourette syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tourette syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- In August 2021, Noema Pharma announced the initiation of its first clinical trial, a Phase IIa dose ranging study of the PDE10A inhibitor NOE-105 in Tourette syndrome. The Allevia trial is a multi-center 12-week prospective study to evaluate the safety and efficacy of once a day NOE-105, one of Noema’s extensive pipeline of products in-licensed from Roche, at a daily dose range of 5mg to15mg in adult male patients with Tourette syndrome.
- In February 2022, Asarina Pharma announced that ‘First Patient First Visit’ has taken place in its phase IIa clinical study in Tourette syndrome at Bispebjerg University Hospital, Copenhagen. The Asarina compound being trialled, Sepranolone, is an endogenous neurosteroid that has already demonstrated a strong safety profile in previous clinical studies. In preclinical studies it was found to reduce tics effectively without inducing any motor side effects.
This segment of the Tourette syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tourette syndrome Emerging Drugs
- Ecopipam: Emalex Biosciences
- SCI-110: SciSparc
Further product details are provided in the report……..
Tourette syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Tourette syndrome drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Tourette syndrome
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
- Molecule Type
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
- Product Type
Tourette syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tourette syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tourette syndrome drugs.
Tourette syndrome Report Insights
- Tourette syndrome Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Tourette syndrome drugs?
- How many Tourette syndrome drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tourette syndrome?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tourette syndrome therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Tourette syndrome and their status?
- What are the key designations that have been granted to the emerging drugs?
- Emalex Biosciences
- Noema Pharma
- Asarina Pharma
- Teva Pharmaceutical
- SciSparc
- EuMentis Therapeutics
- Synendos Therapeutics
- Ecopipam
- NOE-105
- Sepranolone
- Deutetrabenazine
- SCI-110
- EM-221
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Tourette syndrome: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Tourette syndrome – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Ecopipam: Emalex Biosciences
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- SCI-110: SciSparc
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Tourette syndrome Key Companies
- Tourette syndrome Key Products
- Tourette syndrome- Unmet Needs
- Tourette syndrome- Market Drivers and Barriers
- Tourette syndrome- Future Perspectives and Conclusion
- Tourette syndrome Analyst Views
- Tourette syndrome Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.